Anlotinib

Drug Profile

Anlotinib

Alternative Names: AL-3818; ALTN; Anlotinib hydrochloride

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advenchen Laboratories; Jiangsu Chia-Tai Tianqing Pharmaceutical
  • Developer Advenchen Laboratories; Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alveolar soft part sarcoma; Colorectal cancer; Gastric cancer; Leiomyosarcoma; Non-small cell lung cancer; Synovial sarcoma; Thyroid cancer
  • Phase II Hepatocellular carcinoma; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma
  • Phase I/II Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 17 Aug 2017 Chemical structure information added
  • 18 Jun 2017 Phase III clinical trials in Alveolar soft part sarcoma in USA (PO) (NCT03016819)
  • 18 Jun 2017 Phase III clinical trials in Leiomyosarcoma in USA (PO) (NCT03016819)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top